| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 2215 PILGRIM MILL CIR | CUMMING | GA | 30041-4841 | FORSYTH | USA | R41CA232779 | Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity | 000 | 1 | NIH | 6/13/2023 | $0 |
| | 2023 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 2215 PILGRIM MILL CIR | CUMMING | GA | 30041-4841 | FORSYTH | USA | R42CA192656 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | 000 | 3 | NIH | 6/12/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 2215 PILGRIM MILL CIR | CUMMING | GA | 30041-4841 | FORSYTH | USA | R42CA192656 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | 000 | 3 | NIH | 3/10/2021 | $0 |
| | 2021 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 2215 PILGRIM MILL CIR | CUMMING | GA | 30041-4841 | FORSYTH | USA | R42CA192656 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | 001 | 3 | NIH | 8/18/2021 | $0 |
| | 2021 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 2215 PILGRIM MILL CIR | CUMMING | GA | 30041-4841 | FORSYTH | USA | R41CA232779 | Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity | 000 | 1 | NIH | 9/24/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | SIGNALRX PHARMACEUTICALS, INC. | 2215 PILGRIM MILL CIR | CUMMING | GA | 30041-4841 | FORSYTH | USA | R43CA240057 | Overcoming BTK inhibitor resistance in B-cell malignancies | 000 | 1 | NIH | 4/25/2020 | $0 |
| | 2020 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL UNIT C | SAN DIEGO | CA | 92130-4052 | SAN DIEGO | USA | R41CA232779 | Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity | 000 | 1 | NIH | 6/29/2020 | $0 |
| | 2020 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL UNIT C | SAN DIEGO | CA | 92130-4052 | SAN DIEGO | USA | R42CA192656 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | 000 | 3 | NIH | 6/26/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $299,888 ) |
| | 2019 | 2019 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130-4051 | SAN DIEGO | USA | R43CA240057 | Overcoming BTK inhibitor resistance in B-cell malignancies | 000 | 1 | NIH | 6/10/2019 | $299,888 |
|
| Issue Date FY: 2018 ( Subtotal = $947,449 ) |
| | 2018 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130-4051 | SAN DIEGO | USA | R42CA192656 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | 001 | 3 | NIH | 9/6/2018 | $1,400 |
| | 2018 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130-4051 | SAN DIEGO | USA | R42CA192656 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | 000 | 3 | NIH | 6/11/2018 | $646,311 |
| | 2018 | 2018 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130-4051 | SAN DIEGO | USA | R41CA232779 | Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity | 000 | 1 | NIH | 8/20/2018 | $299,738 |
| | 2018 | 2016 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130-4051 | SAN DIEGO | USA | R41CA206859 | Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors | 000 | 1 | NIH | 5/1/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,320,558 ) |
| | 2017 | 2017 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130-4051 | SAN DIEGO | USA | R42CA192656 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | 000 | 2 | NIH | 7/11/2017 | $1,320,558 |
| | 2017 | 2015 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130-4051 | SAN DIEGO | USA | R41CA192656 | Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors | 000 | 1 | NIH | 10/31/2016 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $299,738 ) |
| | 2016 | 2016 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130 | SAN DIEGO | USA | R41CA206859 | Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors | 000 | 1 | NIH | 9/22/2016 | $299,738 |
|
| Issue Date FY: 2015 ( Subtotal = $209,001 ) |
| | 2015 | 2015 | SIGNALRX PHARMACEUTICALS, INC. | 12545 EL CAMINO REAL | SAN DIEGO | CA | 92130 | SAN DIEGO | USA | R41CA192656 | Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors | 000 | 1 | NIH | 4/8/2015 | $209,001 |
|
|
